by Clare Gerrard | Jan 31, 2023
Neuroendocrine Cancer UK has been made aware that there is an imminent issue regarding the availability of Olatuton® (Octreotide long-acting) somatostatin analogue injections. This is due to a legal issue that has led to the withdrawal of Olutaton®: it will not be... by Leanne Talbot | Aug 15, 2022
The presence and/or treatment of Neuroendocrine Cancer can disrupt normal digestive function – this can impact on our ability to absorb nutrients, including vitamins and minerals, from the food we eat. Malnutrition has been reported in up to 40% of... by Leanne Talbot | Sep 22, 2021
There are a number of treatments available for Neuroendocrine Cancer – but your treatment should be based on your Neuroendocrine Cancer, your general health and your informed choice. Find out more here –... by Leanne Talbot | Sep 1, 2021
There are a number of treatments available for Neuroendocrine Cancer – but your treatment should be based on your Neuroendocrine Cancer, your general health and your informed choice. You can find out more about treatments in Neuroendocrine Cancer here ➡️... by Leanne Talbot | Aug 3, 2021
A publication on the prevalence of self-reported side effects in neuroendocrine tumour patients prescribed somatostatin analogues written by Catherine Bouvier, Tara Whyand and Philippa Davies was featured in the British Journal of Nursing in 2018. Somatostatin... 
